Imagine a future where the onset of Alzheimer’s or Parkinson’s disease could be predicted and effectively treated before symptoms even appear. Neurodegenerative diseases have long remained shrouded in a veil of uncertainty, with definitive diagnoses often coming too late to alter their devastating trajectories. Biomarkers are the beacons of hope in this landscape, potentially revolutionizing…
In a remarkable stride towards advancing healthcare, Canadian innovators have unveiled a groundbreaking artificial intelligence (AI) program to transform the early detection of Amyotrophic Lateral Sclerosis (ALS). Mitsubishi Tanabe Pharma Canada (MTP-CA) takes immense pride in supporting this revolutionary AI technology, which harnesses the power of AI to scrutinize de-identified electronic medical records (EMRs). This…
In a groundbreaking move poised to reshape the landscape of brain disease treatments, CervoMed Inc. (formerly known as Diffusion Pharmaceuticals Inc.) has announced the successful completion of its merger with EIP Pharma Inc. This milestone marks the birth of a dynamic clinical-stage biotechnology company committed to advancing innovative therapies for degenerative diseases. The company’s press…
Roche Launches Legal Battle Against Biogen’s Imitative Biosimilar of Blockbuster Arthritis Drug July 14, 2023 – Roche (ROG.S) and its subsidiary powerhouses have taken a decisive step by initiating legal proceedings against biotech frontrunner Biogen (BIIB.O) in the federal court of Massachusetts. Their grievance centers around Biogen’s audacious attempt to replicate Roche’s highly successful drug…
Introduction: Parkinson’s disease is a progressive neurological disorder affecting millions worldwide. It is characterized by tremors, stiffness, and impaired movement, among other symptoms. Despite decades of research, there is currently no cure for Parkinson’s disease, and limited treatment options are available to patients. However, recent advances in biomarker research offer hope for earlier detection and…